Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with Johns Hopkins University to advance the clinical development of therapies targeting genetically driven diseases. The partnership aims to apply academic innovations into viable treatments, focusing on gene therapy and small molecules. CEO Neil Kumar expressed excitement over leveraging Johns Hopkins' research for potential patient benefits. BridgeBio intends to establish long-term partnerships in biomedical research, reinforcing its commitment to addressing Mendelian diseases, with over 20 programs in its pipeline.
Phoenix Tissue Repair, an affiliate of BridgeBio Pharma (Nasdaq: BBIO), provided updates on its Phase 1/2 study of PTR-01 for recessive dystrophic epidermolysis bullosa (RDEB). The initial cohorts showed that PTR-01 was well tolerated across nine patients, with no serious adverse events reported. Furthermore, a dose-dependent increase in collagen 7 skin deposition was observed. The trial is progressing with a fourth cohort, and results may lead to a six-month open-label study. Dr. Sanuj K. Ravindran has been appointed as the executive chairman, focusing on creating a systemic treatment for RDEB.
BridgeBio Pharma (Nasdaq: BBIO) announced its Q1 2020 financial results, reporting a net loss of $91.9 million, up from $61.2 million in Q1 2019. The company holds $928.4 million in cash and equivalents, ensuring operational stability amid COVID-19 challenges. Clinical trials are ongoing but slowed in enrollment due to the pandemic. BridgeBio aims to file multiple NDAs and INDs later this year. Despite operational hurdles, recent financing raised $550 million, positioning them to progress their pipeline of 20+ drug programs through 2022.
BridgeBio Pharma (Nasdaq: BBIO) will present at the Bank of America Securities 2020 Health Care Conference on May 14, 2020, at 11 AM ET. The presentation will be accessible via a live webcast on the company’s investor page, with a replay available until August 12, 2020. Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and cancers with genetic drivers. The company boasts a robust pipeline of over 20 development programs, ranging from early discovery to late-stage development.
BridgeBio Pharma (Nasdaq: BBIO) announced the granting of stock options and restricted stock units on May 1, 2020. The compensation committee approved awards for five employees, totaling 39,600 stock options with an exercise price of $28.97 and 18,230 restricted stock units. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are part of the 2019 Inducement Equity Plan established in November 2019. BridgeBio focuses on developing treatments for genetic diseases and has a pipeline of over 20 programs.